Absolute terror reigns over many #AVCT shareholders this week- simply because @avacta hasn't announced orders for its LFT yet.

Question: would #AVCT be lining up 30m per month capacity overseas, if it thought its existing 5m per month capacity in the UK wouldn't be filled? 1/13

Many seem obsessed with the UK market, thinking that's the be-all and end-all for #AVCT's AffiDX LFT.

My view is that mgmt had turned its back on the UK market several months ago, when it was apparent that there was, at best, complete ineptitude; or, at worst, corruption... 2/13

...at the top of certain UK Gov bodies. I'm referring to both the continued inexplicable support of Innova, and to the stonewalling of @mologic and UK Diagnostics PLC in general.

The FDA's actions against Innova may well have changed #AVCT's stance re: dealing with HMG. 3/13

Indeed, given AffiDX's world-leading sensitivity, its easy-to-use AN sample collection method, its ability to detect Delta without issue, and its "Made in the UK" tag line - I do think many will question DHSC, if #AVCT's LFT is not used going forward in schools / the NHS. 4/13

If it does, then #AVCT's LFT output could reach 60m+ pm quite quickly.

But instead of getting wound up by potential DHSC contracts, and setting oneself up for potential disappointment, I think the focus should be on reaching that goal of 35m per month sold into EU within Q4 5/13

The fearmongers are out in force on Twitter and the bulletin boards this week, calling for the end to the age of testing. These online platforms can be a great source of info to investors, but equally very dangerous. As it's not financial advice, I do feel comfortable in... 6/13

...advising: filter, mute and block - liberally. It's counter-productive arguing with a troll that wants to be argued with.

As to #COVID19 testing coming to an end - I will repeat the analogy I've used before: 9/11. Airport security was changed materially and irrevocably... 7/13

...in its wake.

The economic, social and psychological damage that #COVID19 has caused to mankind is so extensive and long lasting that the most effective countermeasures - vaccines AND highly accurate rapid testing - will be around for many years.

The current issue... 8/13

...at least in the UK, is that Innova has severely damaged the reputation of the LFT as a tool.

The majority of the public will not yet realize that there are dozens of different LFT models, nor appreciate the gulf of difference in quality between them - so great that... 9/13

...they are hardly comparable. The highest quality LFT may pick up 95+ cases out of 100 of infectious cases with low viral loads. The low quality LFTs may correctly identify <10 of that population.

In time, however, particularly after the UK Gov stops handing out free... 10/13

...LFTs to the public, product quality - and thus brand recognition - will come to the fore. Boris is leaving the handling of #COVID19 to the people going forward: what LFT will people want to use - will they buy for themselves - when they want to visit elderly relatives?

11/13

Major orders for AffiDX will come; of that I have no doubt. But as I Tweeted recently, the even greater benefit to #AVCT of launching the AffiDX #COVID19 LFT is that the global diagnostics industry has now seen what the Affimers Diagnostics platform is capable of. 12/13

@avacta has the global patent over usage of Affimers in Diagnostics into the 2030s. The AffiDX brand has huge growth ahead.

My view: Affimer Diagnostics will ultimately be acquired for (much) more than #AVCT's current mkt cap.

The three Therapeutics platforms: a free ride 13/13